Standardization, regulation, quality assurance and emerging technologies in hemostasis: Issues, controversies, benefits, and limitations

被引:32
作者
Favaloro, Emmanuel J. [1 ]
机构
[1] Westmead Hosp, Dept Haematol, Inst Clin Pathol & Med Res, SWAHS, Westmead, NSW 2145, Australia
关键词
standardization; regulation; laboratory assessments; hemostasis testing; diagnostic practice; quality assurance;
D O I
10.1055/s-2007-971816
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There are many benefits to the overall process of standardization for tests of hemostasis and thrombosis. Nevertheless, it should also be recognized there are several specific problems and limitations to this process, as highlighted in this review. Some of the issues are formidable, but it is hoped that they are not insurmountable. Sometimes, clinical pressures drive diagnostic test processes before they are formally proven to be of clinical value. Such clinical pressures drive diagnostic changes in the hemostasis laboratory, including the incorporation of new and emerging technologies, which in turn drives the need for evolving and effective external quality assurance. Incorporated into the diagnostic or test-performance process are a large number of organizations involved in driving standardization, with the ultimate intention of improving diagnostics, but this process will also have unintended potential for adverse outcomes. Although this review notes many of the benefits to the process, it focuses primarily on those negative factors that are often less obvious but still require attention and process review.
引用
收藏
页码:290 / 297
页数:8
相关论文
共 24 条
[1]   Emerging technologies in hemostasis diagnostics: A report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group [J].
Adams, Murray ;
Ward, Chris ;
Thom, Jim ;
Bianchi, Alessandra ;
Perrin, Emma ;
Coghlan, Douglas ;
Smith, Mark .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (03) :226-234
[2]  
BEHRING ZLB, HIST HAEMATE
[3]   Quality assurance in hemostasis: The perspective from the College of American Pathologists proficiency testing program [J].
Cunningham, Mark T. ;
Brandt, John T. ;
Chandler, Wayne L. ;
Eby, Charles S. ;
Hayes, Timothy E. ;
Krishnan, Jayashree ;
Lefkowitz, Jerry B. ;
Olson, John D. ;
Stasik, Christopher J. ;
Teruya, Jun ;
Van Cott, Elizabeth M. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (03) :250-258
[4]   A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing [J].
Favaloro, EJ ;
Wong, RCW ;
Silvestrini, R ;
McEvoy, R ;
Jovanovich, S ;
Roberts-Thomson, P .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (01) :73-84
[5]   von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: A 15-year journey [J].
Favaloro, EJ .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (02) :191-202
[6]   A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations [J].
Favaloro, EJ ;
Orsag, I ;
Bukuya, W ;
McDonald, D .
PATHOLOGY, 2002, 34 (04) :348-355
[7]   Emerging technologies and quality assurance in hemostasis: A review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program [J].
Favaloro, Emmanuel J. ;
Bonar, Roslyn .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (03) :235-242
[8]   Laboratory monitoring of therapy in von Willebrand disease: Efficacy of the PFA-100 and von Willebrand factor: Collagen-binding activity as coupled strategies [J].
Favaloro, Emmanuel J. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (06) :566-576
[9]   Laboratory identification of von Willebrand disease: Technical and scientific perspectives [J].
Favaloro, Emmanuel J. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (05) :456-471
[10]  
Favaloro Emmanuel J, 2005, Lab Hematol, V11, P174, DOI 10.1532/LH96.05029